Adimab, LLC announced the appointment of Aaron Sato, Ph.D., to the newly created position of Chief Strategy Officer. Dr. Sato will be responsible for guiding marketing strategies and engaging with potential partners across a variety of therapeutic approaches, including Adimab's technology related to monoclonal and multispecific antibody discovery and optimization, T-cell engagers, TCRs, GPCRs and other membrane-obligate targets, as well as other existing and new technology offerings. In addition, Dr. Sato will help lead internal cross-functional efforts to develop competitive intelligence, perform internal and external technology analysis, and drive external technical engagement with drug development companies, key opinion leaders, and industry leaders.
“We are expanding into a growing number of business areas that we are excited about, so we feel that now is the right time to hire additional talent. And it is not often that we have the chance to bring on someone of Aaron Sato's caliber and experience,” said Philip T. Chase, Chief Executive Officer of Adimab. “Aaron's significant technical knowledge as well as his deep business development capabilities complement our leadership team perfectly which is why we have chosen to make him our first c-level hire in over 12 years. We are looking forward to everything that Aaron can bring to the team."
"Adimab has been the undisputed industry leader for well over a decade and the breadth and depth of their technology and expertise is unparalleled," said Dr. Sato. "I am thrilled to join them and in particular, I am excited to help find more opportunities for this amazing group of scientists to collaborate with drug developers all over the world."